Products |
Vizamyl (flutemetamol F-18) Alzheimer's imaging agent
Related Content
Feb. 25, 2025— GE HealthCare has delivered the first patient doses of Flyrcado (flurpiridaz F 18) injection, a unit dose ...
March 03, 2025 
June 18, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...
June 18, 2024 
June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...
June 14, 2024 
October 5, 2023 — Jubilant DraxImage Inc., a wholly-owned subsidiary of Jubilant Pharma Limited, has entered into an ...
October 05, 2023 
PET Technology More Effective Than Angiogram at Determining Need for Coronary Stents, Bypass Surgery
December 1, 2022 — A new method for determining whether patients with heart disease need coronary stents or bypass ...
December 01, 2022 ![Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD)](/sites/default/files/styles/content_feed_medium/public/Screen%20Shot%202022-09-13%20at%203.30.13%20PM.png?itok=2w6OoNd6)
September 14, 2022 — GE Healthcare and Lantheus Holdings Inc have announced that the recent Phase III clinical trial of ...
September 14, 2022 
August 25, 2022 — The results of “A Phase 3, Open-label, Multicenter Study of Flurpiridaz (F18) Injection for Positron ...
August 25, 2022 
June 15, 2022 — Poor functional outcomes after a heart attack can be predicted with a new PET imaging agent, 68Ga-FAPI ...
June 15, 2022 
December 5, 2018 — Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market ...
December 05, 2018 
July 17, 2018 — A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new ...
July 17, 2018